1. Coeberg JWW. Summary and discussion of results. In Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Esteve J, eds. Survival of Cancer Patients in Europe. The Eurocare study. Lyon, IARC Scientific Publications No. 132, 1995, 447–463.
2. Cullinan S, Moertel CG, Wieand HS, et al. A phase 3 trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 1990, 65, 2207–2212.
3. Cytotoxic effects of essential fatty acids (EFA) in mixed cultures of normal and malignant human cells;Begin;Prog Lipid Res,1986
4. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids;Begin;J Natl Cancer Inst,1986
5. Fearon KCH, Falconer JS, Ross JA, et al. An open label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinoleate. Anticancer Res 1996, 16, 867–874.